“Medicare […] will provide limited coverage for the EndoPredict breast cancer gene expression test for the management of post-menopausal women diagnosed with early-stage (TNM stage T1-3, N0-1) estrogen-receptor (ER) positive, Her2-negative breast cancer, who are either lymph node-negative or who have 1-3 positive nodes, and for whom treatment with adjuvant endocrine therapy (e.g., tamoxifen or aromatase inhibitors) is being considered.”
MolDX: EndoPredict Breast Cancer Gene Expression Test (L37311), effective date 1/30/2018.
View LCD
Local Coverage Determination (LCD): MolDX: Pharmacogenomics Testing (L38394)
Local Coverage Article (LCA): Billing and Coding – MolDX: Pharmacogenomic Testing (A58324)
Read Article
Prolaris® Prostate Cancer Genomic AssayLocal Coverage Determination (LCD): MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (L38341)
Prolaris® Prostate Cancer Genomic Assay
Local Coverage Determination (LCD): MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (L38341)
From state licenses to ISO Accreditation, Myriad has several clinical laboratory certifications. You can find them here:
View Lab Accreditations